Central Nervous System (CNS) Therapeutics Market By Disease Type (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

List of Tables

The Central Nervous System (CNS) Therapeutics Market was valued for $114,145.58 million in 2023 and is estimated to reach $199,098.30 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033. The central nervous system (CNS) is a complex network of nerves and cells that play a crucial role in coordinating and regulating the body's activities. It comprises the brain and spinal cord, serving as the primary control center for the entire nervous system. Central nervous system therapeutics aim to alleviate symptoms, improve cognitive function, and slow down disease progression. Central nervous system therapeutics primarily involve the use of drugs to address disorders and imbalances within the central nervous system. The medications target various neurological and psychiatric conditions, ranging from neurodegenerative diseases like Alzheimer's and Parkinson's to mental health disorders such as mood disorders, anxiety, and psychotic disorders.

Central Nervous System (CNS) Therapeutics Market - IMG1

The central nervous system (CNS) therapeutics market is expected to register significant growth, owing to surge in prevalence of CNS disorders, and favorable government initiative such as research grants to support research and innovation. The rise in prevalence of CNS disorders has emerged as a major driver for the central nervous system (CNS) therapeutics market. This can be attributed to the stressful lifestyle, negligence towards mental health, and rise in geriatric population. The aging population, in particular, has witnessed a surge in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. For instance, according to Center for Disease Control and Prevention, it was estimated that around 6.7 million Americans aged 65 years or older had Alzheimer's disease.

Additionally, the modern, fast-paced lifestyle, marked by high stress levels and sedentary habits, has been associated with a heightened risk of mental health disorders like anxiety and depression. For instance, according to National Library of Medicine, in 2021, it was estimated that that more than one in five U.S. adults live with a mental illness. Pharmaceutical companies are increasingly focusing on the discovery and development of novel drugs and therapies targeting various CNS conditions. Breakthroughs in neuroscience and a deeper understanding of the underlying mechanisms of these disorders have paved the way for more effective and targeted treatment options. The demand for CNS therapeutics is expected to surge as patients and healthcare providers seek advanced interventions that not only alleviate symptoms but also address the root causes of the CNS disorders. Thus, the rise in prevalence of CNS disorders is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market.

In addition, favorable government initiatives such as research grants to support research and innovation in treating central nervous system disorders are expected to drive the growth of the market. Governments around the world are recognizing the critical need to address conditions such as neurodegenerative diseases, psychiatric disorders, and neurological disorders, which collectively pose a substantial burden on global healthcare systems. One notable initiative driving the research is the provision of research grants specifically dedicated to advancing our understanding of the central nervous system and developing novel therapeutic interventions. The research grants serve as a catalyst for scientific exploration, fostering collaboration between researchers, academia, and pharmaceutical companies. For instance, American Parkinson Disease Association, awards research grant of maximum of $75,000 to research scientists. American Parkinson Disease Association Research Grants are intended to support research aimed at developing new insights into the pathophysiology, etiology and treatment of Parkinson's disease.

Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. American Parkinson Disease Association seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation. By providing grants governments agencies are playing a pivotal role in accelerating the development of innovative treatments and therapies. Thus, favorable government initiatives such as research grants are expected to drive the growth of the market.

However, the high cost of the central nervous system (CNS) therapeutic drug has emerged as major concerns restraining the growth of the market. The complex nature of neurological disorders often necessitates sophisticated and specialized therapeutic interventions, leading to elevated research and development expenses. Additionally, the stringent regulatory requirements imposed by health authorities contribute to the lengthy and resource-intensive process of bringing CNS drugs to market. These substantial costs are then transferred to end-users, comprising patients and healthcare systems, thereby limiting accessibility and affordability of the CNS drugs. Thus, the high cost of the central nervous system (CNS) therapeutic drug might restrain the growth of the market.

The central nervous system (CNS) therapeutics market is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, cancer, and others. The mental health segment is further segmented into mental health anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others.

In addition, the neurodegenerative diseases are further classified into Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Biogen Inc, Johnson and Johnson, Eli Lilly and Company Inc, Merck and Co. Inc, F. Hoffmann-La Roche AG, Novartis AG, Takeda Pharmaceuticals, Viatris, UCB, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central nervous system (cns) therapeutics market analysis from 2023 to 2033 to identify the prevailing central nervous system (cns) therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the central nervous system (cns) therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global central nervous system (cns) therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Disease Type

Neurodegenerative Diseases
- Disease Type
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Huntington's Disease
- Amyotrophic Lateral Sclerosis
- Others
Infectious Diseases
CNS Cancer
Others
Neurovascular Diseases
CNS Trauma
Mental Health
- Disease Type
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Johnson and Johnson
Eli Lilly and Company.
Merck & Co Inc
Novartis AG
Biogen
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche AG
Takeda Pharmaceutical Company Ltd.
Viatris Inc.
UCB Pharma

Product Code: A305147

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. High intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of the neurological conditions
  - 3.4.1.2. Rise in awareness and diagnosis of CNS disorders
  - 3.4.1.3. Surge in research and development by key players
- 3.4.2. Restraints
  - 3.4.2.1. High cost of central nervous system (CNS) therapeutics
- 3.4.3. Opportunities
  - 3.4.3.1. Technological advancements in drug delivery

CHAPTER 4: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Neurovascular Diseases
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. CNS Trauma
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Mental Health
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.4.4. Mental Health Central Nervous System (CNS) Therapeutics Market by Disease Type
4.5. Neurodegenerative Diseases
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.5.4. Neurodegenerative Diseases Central Nervous System (CNS) Therapeutics Market by Disease Type
4.6. Infectious Diseases
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
4.7. CNS Cancer
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country

CHAPTER 5: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION

5.1. Overview
- 5.1.1. Market size and forecast By Region
5.2. North America
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by Disease Type
- 5.2.3. Market size and forecast, by country
  - 5.2.3.1. U.S.
  - 5.2.3.1.1. Market size and forecast, by Disease Type
  - 5.2.3.2. Canada
  - 5.2.3.2.1. Market size and forecast, by Disease Type
  - 5.2.3.3. Mexico
  - 5.2.3.3.1. Market size and forecast, by Disease Type
5.3. Europe
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by Disease Type
- 5.3.3. Market size and forecast, by country
  - 5.3.3.1. Germany
  - 5.3.3.1.1. Market size and forecast, by Disease Type
  - 5.3.3.2. France
  - 5.3.3.2.1. Market size and forecast, by Disease Type
  - 5.3.3.3. UK
  - 5.3.3.3.1. Market size and forecast, by Disease Type
  - 5.3.3.4. Italy
  - 5.3.3.4.1. Market size and forecast, by Disease Type
  - 5.3.3.5. Spain
  - 5.3.3.5.1. Market size and forecast, by Disease Type
  - 5.3.3.6. Rest of Europe
  - 5.3.3.6.1. Market size and forecast, by Disease Type
5.4. Asia-Pacific
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by Disease Type
- 5.4.3. Market size and forecast, by country
  - 5.4.3.1. Japan
  - 5.4.3.1.1. Market size and forecast, by Disease Type
  - 5.4.3.2. China
  - 5.4.3.2.1. Market size and forecast, by Disease Type
  - 5.4.3.3. India
  - 5.4.3.3.1. Market size and forecast, by Disease Type
  - 5.4.3.4. Australia
  - 5.4.3.4.1. Market size and forecast, by Disease Type
  - 5.4.3.5. South Korea
  - 5.4.3.5.1. Market size and forecast, by Disease Type
  - 5.4.3.6. Rest of Asia-Pacific
  - 5.4.3.6.1. Market size and forecast, by Disease Type
5.5. LAMEA
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by Disease Type
- 5.5.3. Market size and forecast, by country
  - 5.5.3.1. Brazil
  - 5.5.3.1.1. Market size and forecast, by Disease Type
  - 5.5.3.2. Saudi Arabia
  - 5.5.3.2.1. Market size and forecast, by Disease Type
  - 5.5.3.3. South Africa
  - 5.5.3.3.1. Market size and forecast, by Disease Type
  - 5.5.3.4. Rest of LAMEA
  - 5.5.3.4.1. Market size and forecast, by Disease Type

CHAPTER 6: COMPETITIVE LANDSCAPE

6.1. Introduction
6.2. Top winning strategies
6.3. Product mapping of top 10 player
6.4. Competitive dashboard
6.5. Competitive heatmap
6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

7.1. Johnson and Johnson
- 7.1.1. Company overview
- 7.1.2. Key executives
- 7.1.3. Company snapshot
- 7.1.4. Operating business segments
- 7.1.5. Product portfolio
- 7.1.6. Business performance
7.2. Eli Lilly and Company.
- 7.2.1. Company overview
- 7.2.2. Key executives
- 7.2.3. Company snapshot
- 7.2.4. Operating business segments
- 7.2.5. Product portfolio
- 7.2.6. Business performance
- 7.2.7. Key strategic moves and developments
7.3. Merck & Co Inc
- 7.3.1. Company overview
- 7.3.2. Key executives
- 7.3.3. Company snapshot
- 7.3.4. Operating business segments
- 7.3.5. Product portfolio
- 7.3.6. Business performance
7.4. Novartis AG
- 7.4.1. Company overview
- 7.4.2. Key executives
- 7.4.3. Company snapshot
- 7.4.4. Operating business segments
- 7.4.5. Product portfolio
- 7.4.6. Business performance
- 7.4.7. Key strategic moves and developments
7.5. Teva Pharmaceutical Industries Ltd.
- 7.5.1. Company overview
- 7.5.2. Key executives
- 7.5.3. Company snapshot
- 7.5.4. Operating business segments
- 7.5.5. Product portfolio
- 7.5.6. Business performance
- 7.5.7. Key strategic moves and developments
7.6. F. Hoffmann-La Roche AG
- 7.6.1. Company overview
- 7.6.2. Key executives
- 7.6.3. Company snapshot
- 7.6.4. Operating business segments
- 7.6.5. Product portfolio
- 7.6.6. Business performance
7.7. Takeda Pharmaceutical Company Ltd.
- 7.7.1. Company overview
- 7.7.2. Key executives
- 7.7.3. Company snapshot
- 7.7.4. Operating business segments
- 7.7.5. Product portfolio
- 7.7.6. Business performance
7.8. Viatris Inc.
- 7.8.1. Company overview
- 7.8.2. Key executives
- 7.8.3. Company snapshot
- 7.8.4. Operating business segments
- 7.8.5. Product portfolio
- 7.8.6. Business performance
7.9. UCB Pharma
- 7.9.1. Company overview
- 7.9.2. Key executives
- 7.9.3. Company snapshot
- 7.9.4. Operating business segments
- 7.9.5. Product portfolio
- 7.9.6. Business performance
7.10. Biogen
- 7.10.1. Company overview
- 7.10.2. Key executives
- 7.10.3. Company snapshot
- 7.10.4. Operating business segments
- 7.10.5. Product portfolio
- 7.10.6. Business performance
- 7.10.7. Key strategic moves and developments